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Abstract Background:Monitoring 
response to highly active antiret-
roviral therapy (HAART) in HIV 
infected children using both labo-
ratory and physical growth pa-
rameter is important. But monitor-
ing laboratory parameters could 
sometimes be challenging in  
resource-poor settings as the ma-
chines used for these measure-
ments may not always be func-
tional or the required technical 
expertise be available especially 
in rural areas. Hence, changes in 
weight-for-age (WAZ), height-for
-age (HAZ) and body mass index-
for age (BAZ) Z scores during 
clinic follow-up visits with or 
without changes in absolute CD4 
count, could be used instead of 
viral load measurements as indi-
cators of response to HAART in 
children. 
Objectives: To determine the ef-
fect in children of treatment with 
HAART - on changes in physical 
growth using WAZ, HAZ and 
BAZ and on changes in CD4 
count using absolute CD4 count.  
Methods: Data on demographic/ 
clinical variables, viral load, abso-
lute CD4 count, and weight and 
height measurements done at en-
rolment and at follow-up visits for 
72 eligible children < 15 years 
who were consecutively enrolled 
into HAART were analysed 
Results: After nine months of 
HAART, the median absolute CD4 
count increased by 28.2% and me-
dian WAZ increased by 28.6%. 
The reduction in the proportion of 
children with moderate malnutri-
tion (WAZ < -2) from time of 
HAART commencement to nine 
months after HAART, was by 
61.5% in those without severe im-
mune suppression (SIS) and by 
50% in those with SIS 
Conclusion: This study showed 
that WAZ and absolute CD4 count 
changes could be useful for moni-
toring response to HAART in  
resource –limited settings. 
 
Key words: Growth, Absolute 
CD4 count, Z score, HAART 
Introduction  
 
Human immunodeficiency virus (HIV) infection/
Acquired immunodeficiency syndrome (AIDS) contin-
ues to be a major health problem with a 2011 estimate 
showing that 23.5 million people living with HIV re-
sided in sub-Saharan Africa, representing 69% of the 
global HIV burden .1  In 2011 it was estimated that 
about 3.4 million children  were living with HIV/AIDs 
with 91% of them living in sub-Saharan Africa but only 
28% of them were receiving anti-retroviral treatment 
(ART).2  A 2010 estimate showed that Nigeria had 
440,000 children below the age of 15 years living with 
HIV/AIDS 3 and of which 280,000 need ART but only 
7% were getting it.4  Monitoring response to highly  
active anti-retroviral therapy (HAART) in these few 
children receiving HAART using laboratory (HIV RNA 
viral load and CD4 percentage / absolute CD4 counts) 
and clinical parameters of physical growth is  
important.5  
 
Monitoring using viral load and CD4 percentage/ abso-
lute counts could sometimes be challenging in resource 
poor settings as the machines used for these measure-
ments may not always be functional or the required tech-
nical expertise be available especially in rural areas.6   
Also, viral load measurements are usually more expen-
sive and take a longer time to get the results. 7 Measur-
ing physical growth indices such as weight and heigt, 
which can be used to determine weight-for-age (WAZ),  
2 
height-for-age (HAZ) and body mass index-for age 
(BAZ) Z scores, would be easier to do in routine clini al 
settings during clinic follow-up visits for children on 
HAART than measuring viral load and CD4 percentage/ 
absolute counts. Changes in Z scores during follow-up 
visits with or without changes in absolute CD4 count, 
especially increases in WAZ and HAZ, could be used as 
indicators of response to HAART.5  Very low Z scores 
(Z < -2) in children are indicative of moderate malnutri-
tion which could be wasting (WAZ <-2 or BAZ < -2) or 
stunting (HAZ< -2).8 Children with HIV who have low 
Z scores are expected to improve/ increase their score  
over time while on HAART as clinical evidence of  
response to HAART . 9-11  Similarly, children with low 
absolute CD4 counts including severe immune suppres-
sion are also expected to improve/ increase their count 
as evidence of improved immune response to  
HAART. 12, 13 
 
This study therefore aims to determine the effect in  
children of treatment with HAART: on changes in 
physical growth (weight, height, and body mass index) 
using Z scores (weight-for- age, height- for- age and 
body mass index- for- age z scores) and on CD4 count 







The study site was the Aids Preventive Initiative Nigeria 
(APIN) satellite site at the General Hospital in Shendam. 
Shendam town with a population of 16, 73114 is a rural 
area by definition.15  This satellite site offers HIV care/ 
services to children and adults, predominantly from the 
surrounding villages. Data on clinical and laboratoy 
parameters collected over a 2 ½ year period from Nov
2009 –June 2012 for eligible children < 15 years who 
were consecutively enrolled into treatment with HAART 
were used for the analysis. Eligibility criteria included 
diagnosis for HIV/ AIDS and fulfilment of the criteria 
for commencement of HAART in children, based on the 
Nigeria’s National Guidelines for Paediatric HIV and 
AIDS Treatment and Care.16   The data included: demo-
graphic and clinical variables, viral load, CD4 count and 
anthropometric measurements done at enrolment into 
HAART and at six and nine months  




The independent variables were age, sex, WHO clinical 
stage, HIV-1 RNA viral load, absolute CD4 count and z 
scores (WAZ, HAZ and BAZ). The z scores were  
obtained from the weight and height of the children,  
adjusted for age and sex, using the WHO AnthroPlus 
software17 by importing the variables - weight, height, 
age and sex in the form of a text file into the software. 
We then categorised the Z scores into a binary variable 
using the WHO cut-off of Z < -2 for moderate malnutri-
tion: wasting (WAZ < -2) or stunting (HAZ< -2) or 
wasting (BAZ < -2).8  The dependent variable was used 
in two forms – as a continuous variable and as a cate-
gorical variable in the analysis. As a categorical variable 
the immune status of the child was obtained from the 
absolute CD4 count using the Centers for Disease  
Control and Prevention (CDC) definition18, where 
counts of <750/mm3 for children < 1year, 500/mm3 for 
those one to five years and, <200/mm3 for those > 5 
years were considered as severe immune suppression 
(SIS). As a continuous variable it was the absolute CD4 
count. Only children with follow-up visits of at least 9 
months and have received at least 9 months of HAART 
during the study period were included in the analysis.  
Analysis was done using Stata software version 10 
(Stata Corporation, College Station, Texas, USA). The 
association of each independent variable with both SIS 
and absolute CD4 count was examined in a univariate 
analysis using the Chi-squared test for the associati n 
between categorical variables and the analysis of vari-
ance (ANOVA), respectively.  Paired t test was used to 
examine the difference between the means of two z 
scores and the Kruskal Wallis test for the difference 
between the medians of two z scores. Multivariate logis-
tic regression was used to examine the association be-
tween Z score categories and SIS. Pvalues of <0.05 were







A total of 72 HIV-1 positive children were enrolled into 
the ARV treatment programme with 49% being males. 
The median age of the children was 3.8 years (IQR, 1.7-
9.0) with only 11% below the age of one year. At enrol-
ment into HAART, majority (89.9%) of the children 
were in WHO clinical stage 1 and 74% (51/69) did not
have SIS but 66% had a HIV-1 RNA viral load of >400 
copies /ml. The median viral load at enrolment was 
higher in those who had SIS (127,691 copies/ml) com-
pared to those who did not (2,616 copies/ml). Majority 
of the children were stunted (HAZ < -2) both at com-
mencement (76%) and after 9 months of HAART (82%) 
but in contrast, only 40% of them still remained moder-
ately malnourished (WAZ < -2) after nine months of 
HAART compared to 59% at commencement of 
HAART and only 2.5% of them were wasted (BAZ < -
2) after nine months of HAART compared to 18.2% at 
commencement of HAART. Four out of the 72 children 
died (case fatality rate of 5%) within the 2 ½ years pe-
riod of study while two were lost to follow-up; with two 
dying before completing nine months of HAART  and 
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Table 1: Characteristics of children at enrolment into HAART and at 9 months of commencing HAART according to severe  
immune suppression status 
Note: Clinical stage, viral load were not assessed at 9 months of commencing HAART      **There was no child with clinical stage 4 disease 
*P value for chi squared test or Fisher’s exact test for the association between categorical variables and severe immune suppression 
The median WAZ and BAZ and the median absolute CD4 counts all increased after starting HAART, through six 
months to nine months of commencing HAART but the HAZ did not (Table 2).  
 









*P values for Kruskal Wallis tests for the differenc  between medians 
Parameter (n) At enrolment  
Median (IQR) 
At 6 months  
Median (IQR) 
At 9 months  
Median (IQR) 
P value* 
WAZ (n=144) -2.1 (-3.1, -1.0) -2.1 (-2.7, -1.0) -1.5 (-2.5, -0.1) 0.088 
HAZ (n=169) -3.2 (-4.2, -2.3) -3.5 (-4.6, -2.4) -3.4 (-4.6, -2.5) 0.819 
BAZ (n=169)  0.1 (-1.3, 0.9) 0.5 (-1.4, 1.8) 0.4 (-0.2, 2.3) 0.006 
CD4 count (n=128) 680 (211, 1296) 725 (262, 1140) 872 (403, 1407) 0.414 
4 
Thus, the median absolute CD4 count increased by 
28.2% from 680/mm3 (IQR: 211, 1296) at HAART 
commencement to 872/mm3 (IQR: 403, 1407) after nine 
months of HAART. Also, the median WAZ increased 
by 28.6% from -2.1 (IQR: -3.1, -1.0) at HAART com-
mencement to -1.5 (IQR: -2.5, -0.6) after 9 months of 
HAART which was significant, p= 0.04 while the me-
dian BAZ increased by 300% from 0.1 (IQR: -1.3, 0.9) 
to 0.4 (IQR: -0.2, 2.3), p=0.001; but there was no  
significant change (p=0.60) in the median HAZ which  
decreased by 6% from -3.2 (IQR: -4.2, -2.3 ) to -3.4  
(IQR: -4.6, -2.5) within the same period (Table 3). 
 
Table 3:  A comparison of the median Z scores and absolute 
CD4 counts at enrolment and at 9 months of HAART 
 *P values for Kruskal Wallis tests for the differenc  between medians 
 
A similar pattern was also observed with the mean - 
WAZ, BAZ and HAZ and log absolute CD4 count; the 
mean log absolute CD4 count increased by 13.8% from
845 (SD 743) at start of HAART to 962 (SD 618) after 
nine months of HAART and the increase was  
significant, p = 0.007 (Table4). 
 
Table 4:  A comparison of the mean Z scores and absolute log 
CD4 counts at enrolment and at 9 months of HAART 
*P values for paired t test for the difference betwen two means 
 
The median WAZ and BAZ scores were generally 
higher in those without SIS compared to lower  
scores in those with SIS whether at commencement of 
HAART or after 9 months of HAART but there was no 
such difference observed in the median HAZ scores. 
Among children without SIS the number with moderate 
malnutrition (WAZ < -2) reduced from 26 before 
HAART commencement to 10 after 9 months of 
HAART, a 61.5% reduction; while among those with 
SIS the number reduced from 6 at HAART commence-
ment to three after nine months of HAART, a 50% re-
duction (Table 1). 
 
In the association of SIS with moderate malnutrition 
(WAZ < -2), the odds of not having SIS in children who 
were not malnourished (WAZ > -2) is 1.5 times more at 
start of HAART compared to those who were malnour-
ished (WAZ < -2) (p = 0.622) and this odds increased to 
5.8 after 9 months of receiving HAART (p = 0.679); but 
after adjusting for the confounding effects of age and 
HAZ in a multivariable logistic regression analysis, 
these odds became 1.4 (p = 0.167) and 8.7 (p = 0.182) 
Parameter (n) At enrolment 
Median (IQR) 
At 9 months 
Median (IQR) 
P value* 
WAZ (n=103) -2.1 (-3.1, -1.0) -1.5 (-2.5, -0.6) 0.043 
HAZ (n=123) -3.2 (-4.2, -2.3 -3.4 (-4.6, -2.5) 0.603 
BAZ (n=123) 0.1 (-1.3, 0.9) 0.4 (-0.2, 2.3) 0.001 
CD4 count (n=113) 680 (211, 1296) 872 (403, 1407) 0.386 
Parameter (n) At enrolment 
Mean (SD) 
At 9 months 
Mean (SD) 
P value* 
WAZ (n=47) -2.1 (1.5) -1.5 (1.6) 0.012 
HAZ (n=53) -3.3 (1.8) -3.5 (1.7) 0.283 
BAZ (n=53) -0.3 (2.1) 0.9 (2.0) 0.001 
Log CD4 count 
(n=43) 
845 (743) 962 (618) 0.007 
respectively, (Table 5). 
 
Table 5: Associations of WAZ and HAZ groups with severe 
immune suppression status at enrolment and at 9 months f 
HAART 






Overall, the 72 HIV-1 positive children enrolled into 
HAART had an improvement/ increase in their growth 
parameters and absolute CD4 counts after 9 months on 
HAART -the median absolute CD4 count increased by 
28.2%, median WAZ increased by 28.6% and median 
BAZ increased by 300% but with no significant change 
in the median HAZ. The median WAZ and BAZ were 
generally higher in those without SIS than in those with 
SIS but there was no such difference observed in the 
median HAZ. The reduction in the proportion of chil-
dren with moderate malnutrition (WAZ < -2) from time 
of HAART commencement to 9 months after HAART, 
was 61.5% in those without SIS and 50% in those with 
SIS. 
 
Our finding of an increase of 28.2%, in absolute CD4 
count after 9 months of ART is comparable to similar 
findings in several studies where absolute CD4 count/
CD4 % was noted to increase from after at least 6 
months of ART. 9, 12, 13 This is the expected immunologi-
cal response to ART. For instance in the study by Bolton
-Moore et al,12 the mean CD4 % increased from 12.9% 
at enrolment into HAART to 23.7% after 6 months of 
HAART (an increase of 83.7%) among 2,398 children 
receiving HAART. These studies also agreed with our 
finding of increase in growth showing as increase in 
WAZ following ART but contrasts with our observation 
of no change in HAZ. The lack of a significant change 
in the median HAZ in our study could be attributed o 
two factors. Firstly, at the start of HAART, more of the 
children (76%) were stunted (HAZ <-2) compared to 
fewer (59%) who were wasted (WAZ < -2) and increase 
in height usually lags behind increase in weight over 
time. Thus, since the follow up time used in our study 
was only 9 months we may not see a significant increase 
in height compared to weight. Another possible explana-
tion for the lack of change in HAZ is that our sample 
size was smaller (72) compared to the larger sizes us d 
in the analyses in the above studies, particularly the one  











( >-2 vs < -2) 
54   1.5 (0.3-6.5) 0.622 51  1.4 (0.3-6.9) 0.679 
HAZ 
( > -2 vs < -2) 
66   1.8 (0.5-7.5) 0.384 51  1.3 (0.2-8.2) 0.772 
  
After 9 Months  
WAZ of 
HAART 
( >-2 vs < -2) 
32   5.4 (0.5-59) 0.167 32  8.7 (0.4-207) 0.182 
HAZ 
( >-2 vs < -2) 
40  1.3 (0.1-
13.2) 
0.806 32  0.5 (0.02-11.8) 0.665 
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by Bolton-Moore et al,12 where the sample size was 
2,398. The observed decrease in the proportion of chil-
dren with moderate malnutrition after 9 months of 
HAART in our study, is the expected improvement in 
nutritional status in response to HAART seen in other 
studies. 5, 9-13 A potent and efficient HAART regimen is 
usually expected to reverse a poor nutritional statu  in 
children with HIV infection.5 
 
Despite using absolute CD4 count in our study as 
against the more commonly used CD4 % in children in 
most studies9, 11-13, our result of an overall progressive 
increase in absolute CD4 with ART after months of 
ART was similar to the increase in CD4 % seen in these 
studies. The use of absolute CD4 count as in our study 
could prove useful in certain situations in rural areas of 
resource- poor settings were the machines used for these 
measurements may not always be able to do CD4 % due 
to the lack of technical expertise6 or because the ma-
chines use cheaper and simpler technologies that are 
able to do only absolute CD4 count.19 However, one 
study supports our use of absolute CD4 count – this 
study by Boyd K et al which analysed a very large data 
collected from several multi-centre longitudinal trials 
and cohort studies showed that absolute CD4 count was 
more useful than CD % in deciding when to start ART 
in HIV-1 infected children.20 
 
One of the limitations of our study is the small sample 
size which would explain why we did not find any sig-
nificant difference between the median HAZ at start of 
treatment and after 9 months of HAART as seen in most 
studies.9, 11, 12   Again the small sample size could ex-
plain the lack of statistical significance we noticed in our 
study in the association of WAZ or HAZ with severe 
immune suppression despite the very large odds ratios 
(Table 5). The lack of significance in the association 
between WAZ and severe immune suppression could be 
attributed to some unknown confounders in our study 
which we could not measure, as there was a reduction in 






The growth parameters in children - WAZ and BAZ 
increased significantly after 9 months of receiving 
HAART and so was the absolute CD4 count but no 
change was observed for HAZ.  Also, HAART lead to a  
reduction in the proportion of children with moderat  
malnutrition (WAZ < -2) both in those without SIS and 
those with SIS. Thus, the WAZ and absolute CD4 count 
could be useful for monitoring response to ART in re-
source –limited settings. 
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